ウイルス不活性化市場の市場規模、シェア、動向分析レポート：製品・サービス別、用途別、最終用途別、地域別、セグメント別予測、2025年～2030年

ウイルス不活性化市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のウイルス不活性化市場規模は、2025～2030年にかけて11.58%のCAGRを記録し、2030年までに13億7,160万米ドルに達すると推定されています。

製薬・バイオ医薬品企業数の増加、FDAによる医薬品承認の増加、ライフサイエンス産業の成長、新規治療や医薬品開発に対する政府資金の増加が、成長の主要要因の一部です。

製薬・バイオ医薬品産業は、企業数の着実な増加、新薬の上市、新薬の発見により、大きな成長を遂げています。世界の疾病数の増加に伴い、新薬や治療法の改善に対するニーズが世界的に高まっています。疾病治療のための新治療法を見つける必要性と相まって、主要企業による研究開発への投資が増加していることが、製薬・バイオ医薬品企業の巨大な成長に寄与し、成長を加速させています。

新薬は、健康上の利点を高めるために企業によって開発されています。世界中の人々のライフスタイルが変化し、座りっぱなしの生活習慣が定着したことが、治療のために医薬品や治療法を必要とする慢性疾患の増加の主要原因となっています。FDAによると、2014年には41の新薬が承認され、翌年には45の新薬が承認されました。このことも成長に寄与しています。

近年、製薬・バイオテクノロジー産業には莫大な資金が投入されています。新薬や治療法の開発には民間企業が大きく貢献しているが、新治療法の研究開発に対する政府支出も増加しています。資金提供の増加は、ここ数年のFDA承認数の増加にもつながっています。これらすべての要因が、ウイルス不活性化市場の巨大な成長に寄与しています。

ウイルス不活化市場のレポートハイライト

• キット・試薬製品セグメントは、2024年に57.37%の最大収益シェアで市場をリードしました。
• 用途別では、ワクチン・治療セグメントが2024年に34.41%の最大収益シェアを占め、遺伝子治療や幹細胞研究などの研究開発用途への投資が増加していることに起因しています。
• 2024年には、製薬・バイオテクノロジー企業セグメントが38.51％の最大収益シェアで市場をリードしました。
• 北米が最大のシェアを占めたのは、慢性疾患の発生を抑制するための医療改革とともに、有力企業が存在し、洗練されたインフラが利用可能なためです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ウイルス不活化の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 産業分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 ウイルス不活化市場：製品・サービス別、推定・動向分析

• 製品・サービスセグメントダッシュボード
• 世界のウイルス不活化市場の製品・サービス変動分析
• 世界のウイルス不活化市場規模と動向分析、製品・サービス別、2018～2030年
• キット・試薬
• システムと付属品
• サービス

第5章 ウイルス不活化市場：用途別、推定・動向分析

• 用途セグメントダッシュボード
• 世界のウイルス不活化市場の用途変動分析
• 世界のウイルス不活化市場規模と動向分析、用途別、2018～2030年
• ワクチン・治療
• 幹細胞製品
• 血液と血液製品
• ティッシュ/ティッシュ製品
• 細胞と遺伝子治療

第6章 ウイルス不活化市場：最終用途別、推定・動向分析

• 最終用途セグメントダッシュボード
• 世界のウイルス不活化市場の最終用途変動分析
• 世界のウイルス不活化市場規模と動向分析、最終用途別、2018～2030年
• 製薬・バイオテクノロジー企業
• CRO
• 学術研究機関
• その他

第7章 ウイルス不活化市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測と動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参入企業
• 企業市況分析、2024年
• 参入企業概要
  • Charles River Laboratories, Inc.
  • Clean Cells
  • Cytiva（Danaher Corporation）
  • Merck KGaA
  • Mettler Toledo
  • Parker Hannifin Corp
  • Rad Source Technologies Inc
  • Sartorius AG
  • Texcell SA
  • Vironova AB

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 4 Global viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 5 Global viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 6 Global viral inactivation market, by region, 2018 - 2030 (USD Million)
• Table 7 North America viral inactivation market, by country, 2018 - 2030 (USD Million)
• Table 8 North America viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 9 North America viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 10 North America viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 11 U.S. viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 12 U.S. viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 13 U.S. viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 14 Canada viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 15 Canada viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 16 Canada viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 17 Mexico viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 18 Mexico viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 19 Mexico viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 20 Europe viral inactivation market, by country, 2018 - 2030 (USD Million)
• Table 21 Europe viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 22 Europe viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 23 Europe viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 24 UK viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 25 UK viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 26 UK viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 27 Germany viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 28 Germany viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 29 Germany viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 30 France viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 31 France viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 32 France viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 33 Italy viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 34 Italy viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 35 Italy viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 36 Spain viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 37 Spain viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 38 Spain viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 39 Denmark viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 40 Denmark viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 41 Denmark viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 42 Sweden viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 43 Sweden viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 44 Sweden viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 45 Norway viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 46 Norway viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 47 Norway viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific viral inactivation market, by country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 52 Japan viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 53 Japan viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 54 Japan viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 55 China viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 56 China viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 57 China viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 58 India viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 59 India viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 60 India viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 61 Australia viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 62 Australia viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 63 Australia viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 64 Thailand viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 65 Thailand viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 66 Thailand viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 67 South Korea viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 68 South Korea viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 69 South Korea viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 70 Latin America viral inactivation market, by country, 2018 - 2030 (USD Million)
• Table 71 Latin America viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 72 Latin America viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 73 Latin America viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 74 Brazil viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 75 Brazil viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 76 Brazil viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 77 Argentina viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 78 Argentina viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 79 Argentina viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa viral inactivation market, by country, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 84 South Africa viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 85 South Africa viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 86 South Africa viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 90 UAE viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 91 UAE viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 92 UAE viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 93 Kuwait viral inactivation market, by product & service, 2018 - 2030 (USD Million)
• Table 94 Kuwait viral inactivation market, by application, 2018 - 2030 (USD Million)
• Table 95 Kuwait viral inactivation market, by end use, 2018 - 2030 (USD Million)
• Table 96 Participant's overview
• Table 97 Financial performance
• Table 98 Key companies undergoing expansions
• Table 99 Key companies undergoing acquisitions
• Table 100 Key companies undergoing collaborations
• Table 101 Key companies launching new product & services
• Table 102 Key companies undertaking other strategies

List of Figures

• Fig. 1 Viral inactivation market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Market outlook
• Fig. 8 Segment snapshot
• Fig. 9 Competitive landscape snapshot
• Fig. 10 Parent market outlook
• Fig. 11 Viral inactivation market driver analysis
• Fig. 12 Viral inactivation market restraint analysis
• Fig. 13 Viral inactivation market: Porter's analysis
• Fig. 14 Viral inactivation market: PESTEL analysis
• Fig. 15 Viral inactivation market: Product & service outlook and key takeaways
• Fig. 16 Viral inactivation market: Product & service market share analysis, 2024 - 2030
• Fig. 17 Global viral inactivation market for kits and reagents, 2018 - 2030 (USD Million)
• Fig. 18 Global viral inactivation market for systems & accessories, 2018 - 2030 (USD Million)
• Fig. 19 Global viral inactivation market for services, 2018 - 2030 (USD Million)
• Fig. 20 Viral inactivation market: Application outlook and key takeaways
• Fig. 21 Viral inactivation market: Application market share analysis, 2024 - 2030
• Fig. 22 Global viral inactivation market for vaccines and therapeutics, 2018 - 2030 (USD Million)
• Fig. 23 Global viral inactivation market for stem cell products, 2018 - 2030 (USD Million)
• Fig. 24 Global viral inactivation market for blood and blood products, 2018 - 2030 (USD Million)
• Fig. 25 Global viral inactivation market for tissue/tissue products, 2018 - 2030 (USD Million)
• Fig. 26 Global viral inactivation market for cellular and gene therapy, 2018 - 2030 (USD Million)
• Fig. 27 Viral inactivation market: End use outlook and key takeaways
• Fig. 28 Viral inactivation market: End use market share analysis, 2024 - 2030
• Fig. 29 Global viral inactivation market for pharmaceutical and biotechnology companies, 2018 - 2030 (USD Million)
• Fig. 30 Global viral inactivation market for CROs, 2018 - 2030 (USD Million)
• Fig. 31 Global viral inactivation market for academic & research institutes, 2018 - 2030 (USD Million)
• Fig. 32 Global viral inactivation market for others, 2018 - 2030 (USD Million)
• Fig. 33 Regional marketplace: Key takeaways
• Fig. 34 North America viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 U.S. viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Canada viral inactivation, 2018 - 2030 (USD Million)
• Fig. 37 Mexico viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Europe viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 UK viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Germany viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 France viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Italy viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Spain viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Denmark viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Sweden viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Norway viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Asia-Pacific viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Japan viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 China viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 India viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Australia viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Thailand viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 South Korea viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Latin America viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Brazil viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Argentina viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 MEA viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 58 South Africa viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Saudi Arabia viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 60 UAE viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 Kuwait viral inactivation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 62 Key company categorization
• Fig. 63 Company market positioning
• Fig. 64 Market participant categorization
• Fig. 65 Strategy framework

Viral Inactivation Market Growth & Trends:

The global viral inactivation market size is estimated to reach USD 1,371.6 million by 2030, registering a CAGR of 11.58% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.

Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.

Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.

Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the viral inactivation market.

Viral Inactivation Market Report Highlights:

• The kits & reagents product segment led the market with the largest revenue share of 57.37% in 2024, attributed to the rise in biopharmaceutical and biotechnological companies worldwide.
• By application, the vaccines and therapeutics segment held the largest revenue share of 34.41% in 2024, attributed to the rising investments in R&D applications such as gene therapy and stem cell research.
• In 2024, the pharmaceutical and biotechnology companies segment led the market with the largest revenue share of 38.51%, attributed to the growth of pharmaceutical and biopharmaceutical companies.
• North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Viral Inactivation Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Biopharmaceuticals
    • 3.2.1.2. Technological Advancements in Viral Inactivation
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Viral Inactivation Techniques
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Viral Inactivation Market: Product & Services Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global Viral Inactivation Market Product & Service Movement Analysis
• 4.3. Global Viral Inactivation Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Kits & Reagents
  • 4.4.1. Kits & Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Systems & Accessories
  • 4.5.1. Systems & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Viral Inactivation Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Viral Inactivation Market Application Movement Analysis
• 5.3. Global Viral Inactivation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Vaccines & Therapeutics
  • 5.4.1. Vaccines & Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Stem Cell Products
  • 5.5.1. Stem Cell Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Blood & Blood Products
  • 5.6.1. Blood & Blood Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Tissue/ Tissue Products
  • 5.7.1. Tissue/ Tissue Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Cellular and Gene Therapy
  • 5.8.1. Cellular and Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Viral Inactivation Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Viral Inactivation Market End Use Movement Analysis
• 6.3. Global Viral Inactivation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnological Companies
  • 6.4.1. Pharmaceutical & Biotechnological Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. CROs
  • 6.5.1. CROs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Academic and Research Institutes
  • 6.6.1. Academic and Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Viral Inactivation Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.4. North America
  • 7.4.1. North America Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Thailand Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. South Korea
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. South Korea Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Participant's Overview
  • 8.3.1. Charles River Laboratories, Inc.
    • 8.3.1.1. Participant's Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product/Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Clean Cells
    • 8.3.2.1. Participant's Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product/Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Cytiva (Danaher Corporation)
    • 8.3.3.1. Participant's Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product/Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Merck KGaA
    • 8.3.4.1. Participant's Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product/Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Mettler Toledo
    • 8.3.5.1. Participant's Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product/Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Parker Hannifin Corp
    • 8.3.6.1. Participant's Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product/Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Rad Source Technologies Inc
    • 8.3.7.1. Participant's Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product/Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Sartorius AG
    • 8.3.8.1. Participant's Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product/Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Texcell SA
    • 8.3.9.1. Participant's Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product/Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Vironova AB
    • 8.3.10.1. Participant's Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product/Service Benchmarking
    • 8.3.10.4. Strategic Initiatives